Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients.
Heffron
T G
TG
Division of Liver Transplantation, Emory University Hospital, Atlanta, Georgia, USA.
Pillen
T
T
Smallwood
G A
GA
Martinez
E
E
de Vera
M E
ME
Romero
R
R
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D016022:Case-Control Studies; D002648:Child; D000077561:Daclizumab; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007668:Kidney / Q000502:physiology; D007674:Kidney Diseases / Q000276:immunology / Q000517:prevention & control*; D016031:Liver Transplantation / Q000276:immunology / Q000502:physiology; D008297:Male; D011183:Postoperative Complications / Q000276:immunology / Q000517:prevention & control*; D011446:Prospective Studies; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D016559:Tacrolimus